I have had the tremendous good fortune of strong leadership throughout my career.
Craig Dashefsky
Executive Director, Global Performance Management and Business Planning, Schering-Plough
I have had the tremendous good fortune of strong leadership throughout my career. I have great admiration for the leaders, bosses, and colleagues I have had and/or continue to work with. I've learned a great deal from them, and they continue to inspire me today. And I consider myself privileged that these highly respected leaders had confidence in my ability to deliver. As an executive, I believe the key is to never lose sight of the details. While you make it a point to hire the best people to carry out the critical aspects of execution, as a leader you have to have an eye toward both implementing the right strategies and ensuring successful execution of them.
I am particularly proud of a recent opportunity I had to lead a cross-functional team in the strategic design and implementation of a new customer-centered selling model at Schering-Plough. We transformed our commercial selling model to deliver greater incremental value to our customers and position our sales representatives to succeed in a dynamic environment. Nearly one year after implementation, I am pleased to say that we are delivering exceptional customer value and have improved our organizational effectiveness. Our US sales team made it happen, and I am delighted to have played a role in this success.
We work very hard to stay in tune with what our customers need. With the nuances in local markets, it's the companies that understand their customers' specific business environment, and deliver value to them, that will ultimately succeed.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.